Peripheral mRNA expression of pluripotency markers in bipolar disorder and the effect of long-term lithium treatment

Pharmacol Rep. 2016 Oct;68(5):1042-5. doi: 10.1016/j.pharep.2016.06.006. Epub 2016 Jul 26.

Abstract

Background: The aim was to evaluate the peripheral mRNA expression of pluripotency master transcriptional factors such as octamer-binding transcription factor 4 (Oct4), sex-determining region Y-box 2 (Sox2) and homeobox protein Nanog, in patients with bipolar disorder (BD), and the effect of long-term lithium treatment.

Methods: Fifteen BD patients (aged 53±7years) not treated with lithium, with duration of illness>10years, 15 BD patients (aged 55±6years) treated with lithium for 8-40 years (mean 16years) and 15 control subjects (aged 50±5years) were included. Assessment of the mRNA levels of pluripotency markers (Oct-4, Sox 2 and Nanog) was performed, using the Real-time quantitative reverse transcription PCR (RQ-PCR) procedure, and the number of CD34+ very small embryonic-like stem cells (VSELs) was measured by flow cytometric analysis.

Results: In those BD patients not treated with lithium the expression of all three pluripotency genes was significantly higher than that in the control subjects. Oct-4, Sox2 and Nanog also positively correlated with the number of CD34+ VSELs/[ul] in this group. In the lithium-treated patients the mRNA levels of Nanog were significantly higher than in the control individuals and correlated with the number and % of CD34+ VSELs.

Conclusions: The overexpression of the pluripotency master transcriptional factors in patients with a long duration of BD not treated with lithium, may contribute to the pathogenesis of the illness and make them potential biological markers of BD. Long-term lithium treatment may attenuate these excessive regenerative processes, especially in relation to the transcription factors Oct-4 and Sox2.

Keywords: Nanog; Oct-4; Sox 2; bipolar disorder; lithium.

MeSH terms

  • Biomarkers / metabolism*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / metabolism*
  • CD3 Complex / metabolism
  • Embryonic Stem Cells / drug effects
  • Embryonic Stem Cells / metabolism
  • Female
  • Humans
  • Lithium / therapeutic use*
  • Male
  • Middle Aged
  • Nanog Homeobox Protein / metabolism
  • Octamer Transcription Factor-3 / metabolism
  • RNA, Messenger / metabolism*
  • SOXB1 Transcription Factors / metabolism

Substances

  • Biomarkers
  • CD3 Complex
  • NANOG protein, human
  • Nanog Homeobox Protein
  • Octamer Transcription Factor-3
  • RNA, Messenger
  • SOX2 protein, human
  • SOXB1 Transcription Factors
  • Lithium